Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
/
WuXi Biologics (Cayman)
2269
WuXi Biologics (Cayman)
Western Dependence And Overcapacity Will Threaten Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 26 Analysts
Published
23 Jun 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
HK$23.34
39.8% overvalued
intrinsic discount
20 Aug
HK$32.62
1Y
204.3%
7D
9.5%
Loading
1Y
204.3%
7D
9.5%
Author's Valuation
HK$23.3
39.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
HK$23.3
39.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
28b
2014
2017
2020
2023
2025
2026
2028
Revenue CN¥28.4b
Earnings CN¥5.0b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
13.23%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.39%
Calculation
CN¥4.98b
Earnings '28
x
21.13x
PE Ratio '28
=
CN¥105.13b
Market Cap '28
CN¥105.13b
Market Cap '28
/
3.96b
No. shares '28
=
CN¥26.55
Share Price '28
CN¥26.55
Share Price '28
Discounted to 2025 @ 7.39% p.a.
=
CN¥21.44
Fair Value '25
CN¥21.44
Fair Value '25
Converted to HKD @ 1.0889 CNY/HKD Exchange Rate
=
HK$23.35
Fair Value '25